A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
← catalyst calendarSponsored by BioAtla, Inc. (industry) · BCAB — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
320estimated
Sites
12
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-03 | actual | When the study began enrolling |
| Primary completion | 2025-03-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- NSCLC
- Melanoma
Interventions
- Biological: BA3071
- Biological: Nivolumab
- Biological: Pembrolizumab
- Drug: Pemetrexed (Alimta)
Primary outcomes
what the primary-completion date above is the date OFAssess dose limiting toxicity as defined in the protocol
measured Up to 24 months
Assess maximum tolerated dose as defined in the protocol
measured Up to 24 months
Frequency and severity of AEs and/or SAEs
measured Up to 24 months
Confirmed overall response rate (ORR) per RECIST v1.1
measured Up to 24 months
Permalink · BCAB's whole pipeline · Catalyst calendar · Every registered study · What changed